Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary study

Thrombosis Research

Volumn 119, Issue 2, 2007, Pages 241-245

  Uszyński, Waldemar ^a   Uszyński, Mieczysław ^b   Zekanowska, Ewa ^b  

^a Regional Hospital in Włocławek   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Amniotic fluid; Blood plasma; Pregnancy; TAFI

Indexed keywords

ANTIGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AMNION FLUID; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DELIVERY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN CLOT; GROUPS BY AGE; HUMAN; LABOR; MATERNAL BLOOD; MEASUREMENT; NORMAL HUMAN; PHYSIOLOGY; PLASMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AMNIOTIC FLUID; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; HUMANS; LABOR, OBSTETRIC; PARTURITION; PREGNANCY;

EID: 33751351327     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.01.012     Document Type: Article

References (22)

1. Morange P.E., Juhan-Vague I., Scarabin P.Y., Alessi M.C., Luc G., Arveiler D., et al. Association between TAFI antigen and Ala I 47Thr polymorphism of the gene and the angina pectoris incidence. Thromb Haemost 89 (2003) 554-560
2. Lau H.K., Segev A., Hegele R.A., Sparkes J.D., Teitel J.M., and Strauss B.H. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thromb Haemost 90 (2003) 1187-1191
3. Van Thiel D.H., George M., and Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 85 (2001) 667-670
4. Lisman T., Leebeek F.-W., Mosnier L.-O., Bouma B.-N., Meijers J.-C., Janssen H.-L., et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121 (2001) 131-139
5. Watanabe R., Wada H., Watanabe Y., Sakakura M., Nakasaki T., Mori Y., et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 104 (2001) 1-6
6. Antović J.P., and Antović A. Does recombinant factor VIIa, apart from overall hemostasis regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. Thromb Haemost 90 (2003) 620-627
7. Campbell W., Okada N., and Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 180 (2001) 162-167
8. Mosnier L.O., Meijers J.C.M., and Bouma B.N. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 85 (2001) 5-11
9. Wang W., Boffa M.B., Bajzar L., Walker J.B., and Nesheim M.E. A study of the mechanism of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 273 (1998) 27176-27181
10. Chetaille P., Kouassi A.D., Morange P.E., and Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 83 (2000) 902-905
11. Chabloz P., Reber G., and Boehlen F. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haemost 115 (2001) 150-152
12. Mousa H.A., Downey C., Alfirevic Z., and Toh C.-H. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost 92 (2004) 1025-1031
13. Watanabe T., Minakami H., Sakata Y., Matsubara S., Sato I., and Suzuki M. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy. Gynecol Obstet Invest 58 (2004) 19-21
14. Antović J.P., Hamad R.R., Antović A., Blombäck M., and Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine foetal growth retardation?. Thromb Haemost 88 (2002) 644-647
15. Alacacioglu I.A., Ozcan M.A., Oglu A.A., Polat M., Yuksel F., Demirkan F., et al. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res 114 (2004) 155-159
16. Uszyński W., Żekanowska E., Szymański W., and Uszyński M. Thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood and blood of mother during labour. Ginek Pol 74 (2003) 1329-1334 [in Polish]
17. Lockwood ChJ., Bach R., Guha A., Zhou X., Miller W.A., and Nemerson Y. Amniotic fluid contains tissue factor, a potent initiator of coagulation. Am J Obstet Gynecol 165 (1991) 1335-1341
18. Uszyński M., Zekanowska E., Uszyński W., and Kuczyński J. Tissue factor (TF) and tissue factor pathway inhibitor (TFP) in amniotic fluid and blood plasma: implications for the mechanism of amniotic fluid embolism. Eur J Obstet Gynecol Rep Biol 95 (2001) 163-166
19. Uszyński W., Uszyński M., and Żekanowska E. Thrombin markers in pregnant women: measurements of prothrombin fragments F1+2 and thrombin-antithrombin III complexes (TAT) in the cord blood, the mother's blood and in amniotic fluid. Ginek Pol 75 (2004) 596-602 [in Polish]
20. Uszyñski M. Thrombin-antithrombin III complexes, thrombin and antithrombin III in amniotic fluid. In: Rao K.A., and Ross M.G. (Eds). Amniotic fluid. 1st edn. (1999), Prism Books Pvt Ltd, Bangalore 151-162
21. Nesheim M. Thrombin and fibrinolysis. Chest 124 (2003) 33S-39S
22. Uszyński M. Fibrinolytic system in amniotic fluid and foetal membranes. In: Rao K.A., and Ross M.G. (Eds). Amniotic fluid. 1st edn. (1999), Prism Books Pvt Ltd, Bangalore 163-175